title: [Antithrombotic therapy in cerebrovascular disorders].
abstract: Warfarin is recommended as primary prophylactic therapy for patients older than 60 years with non-valvular atrial fibrillation and for patients with additional risk factors for thromboembolism. Warfarin should also be given as secondary prophylaxis. Patients with contraindications to warfarin should be given aspirin. Anticoagulant therapy is recommended against progressive ischemic stroke and in cardiogenic cerebral embolism, although conclusive evidence of the benefit is lacking. In the case of transient ischemic attacks and minor stroke, antiplatelet therapy reduces the risk of subsequent stroke by approximately 25 percent. Antiplatelet therapy is probably indicated in cases of acute, stable ischemic stroke.
authors.affiliation: Medisinsk avdeling Aker sykehus, Oslo.
authors.forename: T
authors.initials: T
authors.lastname: Dahl
authors.forename: U
authors.initials: U
authors.lastname: Abildgaard
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D012307:Risk Factors; D015912:Thrombolytic Therapy; D014859:Warfarin / Q000008:administration & dosage
chemical_list: D000925:Anticoagulants; D014859:Warfarin
vernacular_title: Antitrombotisk behandling ved cerebrovaskulaer sykdom.